ViCentra, a European medical device company, has appointed Ian Wells as Chief Financial Officer and Tom West as an Independent Board Member to strengthen its financial and governance foundation. These leadership additions come as ViCentra scales its commercial manufacturing and prepares to expand across Europe and enter the US market. The company recently closed a $98 million Series D financing and launched its smartphone-controlled Kaleido insulin patch pump system. With these appointments, ViCentra aims to accelerate growth, improve unit economics, and increase access to its diabetes care technology.
Elevara Medicines appointed Dr. Mai-Britt Zocca as CEO, succeeding founder Emma Tinsley who will remain on the board. Dr. Zocca brings extensive biotech leadership experience, having led Nasdaq-listed IO Biotech through advanced clinical trials. Elev...
FREELANDER, a British premium automotive brand co-developed by Chery and Jaguar Land Rover, announced its first international market launch in Abu Dhabi, UAE, scheduled for September 2026. This launch marks a key milestone in the brand's global expan...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Retail investors are showing increased bullish sentiment on XRP, reaching a 5-week high in positive comments compared to bearish ones. Despite this optimism, analysts caution that XRP is still in the early stages of a broader bottoming process, requi...
Domino's Pizza reported sales growth in the first quarter of 2026 but missed analyst expectations, signaling vulnerabilities to economic and competitive pressures. The company faces challenges from macroeconomic headwinds and rising competition, whic...
